Louvain-la-Neuve, Belgium, 17 January 2020 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to announce that the Quirónsalud Proton Therapy Center in Madrid, Spain, began treating patients on its IBA Proteus®ONE* on December 26, 2019. These are the first patients to receive proton beam therapy in Spain.
Quirónsalud has been able to treat its first patients following a 12-month ProteusONE installation period. The IBA compact proton therapy system installed in Madrid includes the latest generation Pencil Beam Scanning (PBS), isocenter volumetric imaging (Cone Beam CT) capabilities, as well as the Philips Ambient Experience.
ProteusONE is IBA’s compact intensity modulated proton therapy (IMPT) solution which, due to its open gantry, enables high patient throughput. It benefits from the latest technologies that have been developed with renowned clinical institutions and allows the treatment of patients with a large number of cancer indications.
With this additional center, 34 IBA-equipped proton therapy centers are in operation today – 23 Proteus®PLUS* and 11 ProteusONE.
Olivier Legrain, Chief Executive Officer at IBA,commented: “We are delighted that patients in Spain can now benefit from the most advanced cancer treatment technology. Thanks to our continued ability to install our Proteus®ONE solution in less than 12 months, IBA reinforces its position as the fastest proton therapy provider from contract signature to patient treatment. We look forward to continuing our collaboration with Quirónsalud.”
Marta Cremades, Managing Director at Quirónsalud Proton Therapy Center, added: “We are very pleased to bring this cutting-edge technology available to patients in Spain and to start treating the first patients in Spain using proton therapy and Thanks to this technology, we can destroy the cancer cells while limiting the exposure of healthy tissues surrounding the tumor and reducing the risk of secondary cancers. We look forward to collaborating further with our network of hospitals so that all patients who could benefit from proton therapy can access it.”
***Ends***
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
* Proteus®PLUS and Proteus®ONE are the brand name of Proteus®235.
About Quirónsalud
Quirónsalud is the most important hospital group in Spain and the third in Europe. It is located in 13 different regions and has the most advanced technology. Quirónsalud offers more than 6,200 beds in more than 100 centers, such as Fundación Jiménez Díaz, Hospital Quirónsalud Madrid, Hospital Universitario Dexeus, Ruber, Centro Médico Teknon, Hospital La Luz, Policlínica de Guipúzcoa, etc. Quirónsalud also has a large team of highly specialized professionals of international prestige.
We work in the promotion of teaching (with seven universitary hospitals) and medical scientific research (with the FJD’s Instituto de Investigación Sanitaria, the unique private research center accredited by the Secretaria de Estado de Investigación, Desarrollo e Innovación).
Our care service is organized in units and transversal networks that allow us to optimize our experience developed in the different centers, as well as the clinical translation of our research. Presently, Quirónsalud develops numerous research projects throughout Spain and many of its centers perform a leading role in several fields, by being pioneers in different specialties such as cardiology, endocrinology, gynecology, neurology, oncology, and sports medicine, among others.
More information can be found at: www.quironsalud.es
For further information, please contact:
IBA
Daniel Ernult
Corporate communication & Proton Therapy Marketing Associate
Tel +32 10 201 287
communication@iba-group.com